Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sabcomeline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.86 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.86 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.86 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabcomeline SCHEMBL6628450 | 1.00 | CHRM2 (0.86) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Oxalic Acid SCHEMBL7430158 | 0.93 | CHRM2 (0.86) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Oxalic Acid SCHEMBL7430164 | 0.93 | CHRM2 (0.86) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3843721 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3838658 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7079710 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133975 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7076525 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133982 | 0.93 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6392265 | 0.91 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | claimed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| EP-0392803-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-RE35593-E | THERAPY FOR DERMENTIA | BEECHAM GROUP P.L.C. | 1997-08-19 | — | — | US | disclosed |
| US-5278170-A | Azabicylo oxime compounds | BEECHAM GROUP P.L.C. (GB) | 1994-01-11 | — | — | US | disclosed |
| EP-0392803-A1 | Novel compounds | Beecham Group p.l.c. (GB) | 1990-10-17 | — | — | EP | disclosed |